Business Context and Reporting Period
Company: Molina Healthcare, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Molina is a multi-state managed care organization serving Medicaid, SCHIP, and Medicare populations. As of June 30, 2007, the company operated in California, Michigan, New Mexico, Ohio, Texas, Utah, and Washington. The Indiana health plan ceased operations effective January 1, 2007. Total membership reached 1,076,000.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2007 |
|---|---|---|
| Total Revenue | $613,888 | $1,176,791 |
| Premium Revenue | $607,127 | $1,163,362 |
| Net Income | $13,314 | $22,906 |
| Operating Income | $22,284 | $38,879 |
| Medical Care Ratio | 85.1% | 85.4% |
| G&A Expense Ratio | 10.9% | 11.1% |
| Cash and Cash Equivalents | $471,502 | $471,502 |
| Long-Term Debt | $30,000 | $30,000 |
| Working Capital | $272,763 | $272,763 |
Note: Working Capital calculated as Total Current Assets ($672,142) minus Total Current Liabilities ($399,379).
Material Changes vs. Prior Period
- Revenue Growth: Premium revenue increased 26.5% year-over-year for the quarter and 25.2% for the six-month period. Growth was driven by enrollment increases in Ohio and Texas start-up plans and the acquisition of Cape Health Plan in Michigan.
- Profitability: Net income increased slightly to $13.3 million for the quarter (from $13.2 million) and $22.9 million for the six months (from $21.7 million). Diluted EPS remained flat at $0.47 for the quarter but improved to $0.81 for the six months (from $0.77).
- Medical Care Ratio: The ratio increased to 85.1% for the quarter (from 83.7%) and 85.4% for the six months (from 84.5%). This increase was influenced by high ratios in start-up plans (Ohio and Texas) and a $3.2 million revenue reduction in New Mexico to meet contractual spending requirements.
- Debt Reduction: The company repaid $15 million on its credit facility during the first quarter. Outstanding debt decreased from $45 million at year-end 2006 to $30 million at June 30, 2007.
- Cash Flow: Net cash provided by operating activities surged to $88.0 million for the six months ended June 30, 2007, compared to $38.6 million in the prior year period, largely due to increased deferred revenue in Ohio and timing of claim payments.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued growth in Ohio and Texas but notes uncertainty regarding claims reserves in these start-up plans due to limited payment experience. The company expects to maintain compliance with regulatory capital requirements.
- Unusual Items:
- Impairment Charge: A $782,000 charge was recorded in Q2 2007 for commercial software no longer in use.
- Retroactive Revenue: A $2.9 million benefit was recognized in Q2 2007 from a retroactive premium rate increase in San Diego County, California.
- Prior Period Benefit: Q2 2006 included a $5.0 million benefit from favorable prior period claims development, which is not present in the current period.
- Risks and Contingencies:
- Legal Proceedings: A shareholder derivative action remains pending (amended complaint filed July 2007). A medical malpractice suit is in early stages. A class action regarding pharmacy fees in New Mexico (Starko) has money damages dismissed, with only declaratory relief claims remaining.
- Regulatory: The company faces risks related to government contract renewals, potential funding decreases in Medicaid/SCHIP, and state-specific capital requirements.
- IBNR Estimates: Significant judgment is required for Incurred But Not Reported (IBNR) claims. A 1% change in completion factors could impact net income by approximately $4.0 million.
Investor Verification Checklist
- Start-up Plan Performance: Verify the medical care ratios and claims development for the Ohio and Texas plans, which are currently running above 91% and carry higher uncertainty.
- New Mexico Contract Terms: Confirm the status of the contract amendment regarding the minimum spending requirement that triggered a $3.2 million revenue reduction in Q2.
- San Diego Rate Increase: Assess the sustainability of the retroactive premium revenue benefit received in California.
- Legal Exposure: Monitor the outcome of the shareholder derivative action and the New Mexico pharmacy fee litigation.
- IBNR Sensitivity: Review the actuarial assumptions for claims reserves, noting the disclosed sensitivity of net income to changes in completion factors and PMPM cost estimates.